{"filing":{"accession_number":"0001628280-26-053412","cik":"0001757898","ticker":"STE","company_name":"STERIS plc","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"ste-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1757898/000162828026053412/ste-20260805.htm"},"events":[{"id":25184,"run_id":22852,"accession_number":"0001628280-26-053412","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"STERIS issued a press release on August 5, 2026 announcing financial results for fiscal 2027 first quarter ended June 30, 2026, with revenue growth of 7% to $1.5 billion, diluted EPS of $2.04 (adjusted EPS of $2.59), and segment-level performance metrics across Healthcare, AST, and Life Sciences divisions.","company_name":"STERIS plc","ticker":"STE","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25942,"accession_number":"0001628280-26-053412","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"STERIS issued a press release on August 5, 2026 announcing financial results for the fiscal 2027 first quarter ended June 30, 2026. The disclosure includes revenue growth of 7% to $1.5 billion, diluted EPS of $2.04 (adjusted EPS of $2.59), and segment-level performance metrics across Healthcare, AST, and Life Sciences divisions. This is a standard quarterly earnings announcement attached as Exhibit 99.1 to Item 2.02, which is the designated Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:17:25.933007+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25185,"run_id":22852,"accession_number":"0001628280-26-053412","anchor_item_number":"2.05","event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"STERIS announced a targeted consolidation plan involving closure of chemistry manufacturing and distribution facilities in St. Louis, Missouri, and Plymouth, Minnesota, with anticipated restructuring charges of $55–70 million ($40–50 million cash, $15–20 million non-cash) and completion by fiscal 2030.","company_name":"STERIS plc","ticker":"STE","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25943,"accession_number":"0001628280-26-053412","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"STERIS announced a targeted consolidation plan involving closure of chemistry manufacturing and distribution facilities in St. Louis, Missouri, and Plymouth, Minnesota, with anticipated restructuring charges of $55–70 million ($40–50 million cash, $15–20 million non-cash). Cash expenditures are expected to consist primarily of \"Associate retention, severance and benefits\" plus transition and facility exit costs, with completion by fiscal 2030. This is a classic workforce reduction and operational restructuring with material exit costs disclosed under Item 2.05.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:17:25.933007+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25942,"accession_number":"0001628280-26-053412","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"STERIS issued a press release on August 5, 2026 announcing financial results for the fiscal 2027 first quarter ended June 30, 2026. The disclosure includes revenue growth of 7% to $1.5 billion, diluted EPS of $2.04 (adjusted EPS of $2.59), and segment-level performance metrics across Healthcare, AST, and Life Sciences divisions. This is a standard quarterly earnings announcement attached as Exhibit 99.1 to Item 2.02, which is the designated Item for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:17:25.933007+00:00","company_name":"STERIS plc","ticker":"STE","filing_date":"2026-08-05"},{"id":25943,"accession_number":"0001628280-26-053412","item_number":"2.05","item_title":null,"event_type":"workforce_reduction","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"STERIS announced a targeted consolidation plan involving closure of chemistry manufacturing and distribution facilities in St. Louis, Missouri, and Plymouth, Minnesota, with anticipated restructuring charges of $55–70 million ($40–50 million cash, $15–20 million non-cash). Cash expenditures are expected to consist primarily of \"Associate retention, severance and benefits\" plus transition and facility exit costs, with completion by fiscal 2030. This is a classic workforce reduction and operational restructuring with material exit costs disclosed under Item 2.05.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:17:25.933007+00:00","company_name":"STERIS plc","ticker":"STE","filing_date":"2026-08-05"}]}